Introduction
Glycogen synthase kinase-3s (GSK-3s) are serine/ threonine kinases originally identified as key regulatory kinases that phosphorylate glycogen synthase, downstream of insulin signaling (reviewed in Cohen and Frame [2001] ). There are two mammalian GSK-3 isoforms, GSK-3a and b (Woodgett, 1990) . Isoforms of GSK-3 show high sequence homology with each other across species and GSK-3b homologs display more than 90% sequence similarity within the kinase domain from flies to humans (Woodgett, 1990 ; reviewed in Ali et al. [2001] ). Although the name suggests functions restricted to glycogen synthesis, recently GSK-3 activity has been demonstrated as a key downstream regulator in signaling pathways engaged by many extracellular cues including Wnts, NGF, EGF, and hedgehog (Zhou et al., 2004 ; see reviews by Cohen and Frame [2001] ; Doble and Woodgett [2003] ; Jope and Johnson [2004] ). Genetic studies in Drosophila have confirmed a crucial role for the Drosophila GSK-3 homolog zestewhite3/shaggy in Wnt-induced wing morphogenesis. In mice, a requirement for GSK-3 activity has been more difficult to define in genetic loss of function studies. The initial round of knockout mice targeting GSK-3b has not been maximally informative. The mice die either at mid-or late-embryonic stages with none surviving postnatally (Hoeflich et al., 2000; Stankunas et al., 2003) . Perhaps surprisingly, dramatic defects in morphogenesis of nervous system or other organs have not been reported. The lack of effect of eliminating GSK-3b on morphological development has suggested ''compensation'' via the closely related GSK-3a isoform. However, there is as yet no proof that GSK-3a mediates GSK-3b effects when GSK-3b is missing.
Many GSK-3 substrates require prior phosphorylation by a ''priming'' kinase at a site proximal to the GSK-3 target residue(s). This phosphorylated residue binds to a positively charged pocket on GSK-3 and greatly increases affinity and selectivity for some substrates. The activity of GSK-3 toward such primed substrates can be abolished by a mutation of argine 96 to alanine Twomey and McCarthy, 2006) . Interestingly, most substrates of GSK-3b including glycogen synthase, b-catenin, APC, and CRMP2 are under negative regulation relieved by serine-9 phosphorylation or binding of GSK-3b by Dsh and FRAT in the Wnt signaling pathway (reviewed by Cohen and Frame [2001] , Doble and Woodgett [2003] , Jope and Johnson [2004] ; Yoshimura et al., 2005) . However, phosphorylation of other substrates by GSK-3b including microtubule-associated protein 1B (MAP1B) positively regulates their actions making for a particularly complex regulatory scheme (Lucas et al., 1998; Goold et al., 1999; Gordon-Weeks, 2004, 2005) .
Many GSK-3 substrates are microtubule-associated proteins including APC, CRMP2, MAP1B, microtubuleassociated protein 2 (MAP2), tau, neurofilament, and kinesin light chain (see Jope and Johnson [2004] ; Goold and Gordon-Weeks [2004] ; Zhou and Snider [2005] for reviews). In accordance with these findings, experimentally altering levels of GSK-3b activity has recently been shown to profoundly regulate neuronal morphology in vitro. Thus, globally increasing GSK-3b activity via transfection of a mutant that prevents the inhibitory serine-9 phosphorylation dramatically reduces *Correspondence: wsnider@med.unc.edu neurotrophin-induced DRG and hippocampal axon growth and interferes with hippocampal dendrite/axonal specification (Zhou et al., 2004; Jiang et al., 2005; Yoshimura et al., 2005) . In addition, globally inhibiting GSK-3 activity with well-studied pharmacological blockers has been shown to profoundly influence axonal and dendritic morphology of both PNS and CNS neurons. However, the studies with pharmacological inhibitors published to date have not been entirely consistent with one another. Several studies have indicated that inhibition of GSK-3 activity by Wnts or lithium decreased axon elongation and induced axon branching in DRG and cerebellar neurons (Lucas et al., 1998; Krylova et al., 2002; Owen and Gordon-Weeks, 2003; Goold and Gordon-Weeks, 2005) . Consistent with these results, Shi et al. (2004) observed that global inhibition of GSK-3 activity led to a defect in axon development in hippocampal neurons. However, Wnts also reportedly stimulate the extension of postcrossing commissural axons (Lyuksyutova et al., 2003) . Further, two recent studies showed that formation of multiple long axons was induced in hippocampal cultures in which GSK-3 activity was inhibited (Jiang et al., 2005; Yoshimura et al., 2005) , consistent with the idea that global elimination of GSK-3 activity enhances axon growth. Thus, from the published work to date, it is not entirely clear whether global inhibition of GSK-3b enhances or inhibits axon growth. This issue is critical, as axon growth inhibitory proteins have been shown to activate GSK-3b (Eickholt et al., 2002; Chadborn et al., 2006) . Thus, it is appealing to consider global inhibition of GSK-3 as a treatment option to enhance neural regeneration. An important first issue to settle in relation to such an approach is whether suppression of both GSK-3a and b activities promotes or inhibits axon growth.
We have therefore assessed the role of GSK-3s in the regulation of axon morphogenesis by the careful selection of inhibitors, determining effects over a wide range of concentrations, and by constructing and verifying an shRNA that specifically suppresses synthesis of both GSK-3a and GSK-3b proteins. We found that at low concentration of inhibitors, an axon branching phenotype predominates that is consistent with the polarity phenotype seen by other investigators. However, a high degree of inhibition of GSK-3 activity achieved by high concentrations of 6-bromoindirubin-3 0 -acetoxime as well as a specific peptide inhibitor blocked axon growth from DRG and hippocampal neurons almost completely. Experiments with an shRNA that strongly suppresses both GSK-3a and GSK-3b proteins confirm that strong suppression of GSK-3 activity dramatically reduces axon growth from dissociated neurons and in slice cultures.
As a potential explanation for these results, we examined the effects of eliminating GSK-3 actions toward primed substrates, several of which are implicated in cell polarity. For example, dephosphorylated APC binds to microtubule plus ends (Zumbrunn et al., 2001 ) and performs functions related to stabilization and interactions between microtubules and actin at the leading edge of migrating cells or elongating axons (Zumbrunn et al., 2001; Shi et al., 2004; Zhou et al., 2004) . Dephosphorylated CRMP2 binds to tubulin heterodimers to promote microtubule assembly and is involved in the establishment of axon specification in hippocampal neurons (Yoshimura et al., 2005) . Overexpression of GSK-3 R96A that selectively inhibits GSK-3 activity toward primed substrates (see Doble and Woodgett [2003] for a review) resulted in reduced CRMP2 phosphorylation and axon branching. In contrast, overexpression of a dominant-negative mutant, GSK-3 KM that suppresses all kinase activity (He et al., 1995; Liu et al., 2002) led to the reduced phosphorylation of both CRMP2 and MAP1B and strongly inhibited axon growth. Consistent with this finding, moderate reduction of GSK-3 activity by pharmacological inhibitors was associated with marked effects on primed substrates APC and CRMP2, but only negligible effects on an unprimed substrate MAP1B. We conclude that GSK-3s are essential for axon growth and that differential regulation of GSK-3 substrates can be associated with different morphological outcomes.
Results

Nervous System Development in GSK-3b Null Mice
We first surveyed neuronal development in GSK-3b null mice. These mice die between E16 and P0 (Hoeflich et al., 2000; our unpublished data) . The brain, spinal cord, and DRGs of the null mice (2/2) do not appear grossly different from heterozygote (+/2) littermate controls (see Figures S1A and S1B in the Supplemental Data available with this article online). We assessed axon projections of DRG neurons in null mice (2/2) in vivo by crossing with a sensory axon reporter line Brn3aTau-LacZ (Quina et al., 2005;  Figure 1A ). When assessed at E13.5, we did not see obvious differences from controls in length of trigeminal and DRG projections, invasion of the limb, or other target fields or initiation of tertiary branching.
We also assessed the development of hippocampal neuron polarity which has been shown to be highly regulated by GSK-3 inhibitors (Jiang et al., 2005; Yoshimura et al., 2005) . In hippocampal neuronal cultures from E16 animals maintained for 6 days and stained with antibodies to tau to reveal axons and MAP2 to reveal dendrites, virtually all neurons in GSK-3b null mice exhibited a single long tau + process ( Figures 1B and 1C ).
Both GSK-3a and b Are Expressed throughout the Embryonic Nervous System Phospho-GSK-3a and APC were found at the tips of the hippocampal axons in embryonic cultures from GSK-3b null mice ( Figure S1C ), strongly suggesting ''compensation'' by GSK-3a. Therefore, we examined the in vivo expression of GSK-3 isoforms, GSK-3a and b in the nervous system of E14 to E16 mice ( Figure S2 ). In situ hybridization showed that GSK-3a mRNA is highly distributed within DRGs and spinal cord ( Figure S2B ). Immunohistochemistry revealed that both GSK-3a and b proteins are abundant in DRGs, spinal cord, brain, and the trigeminal ganglion ( Figures 1D and S2C) . Interestingly, we observed an intense staining pattern along the central and peripheral projections of DRGs and the trigeminal ganglion ( Figure 1D ). Western blotting using GSK-3 antibodies confirmed that every tissue that we examined from the nervous system expresses both GSK-3a and b throughout embryonic stages and early postnatal life ( Figure S2D ). Finally, we confirmed (Figure 1E ) that GSK-3a protein is abundant in DRG, spinal cord, and brain from GSK-3b null mice. Taken together, the abundant expression of GSK-3a in the nervous system is consistent with the idea that GSK-3a may ''compensate'' for the function of GSK-3b in the regulation of nervous system development.
Pharmacological Inhibition of GSK-3 Activity Causes Either Branching or Inhibition of NeurotrophinInduced Axon Growth Depending on the Degree of Inhibition As suggested by Figure 1 , it seems necessary to eliminate both GSK-3a and b activities to assess their roles in axon growth. In order to abolish both GSK-3a and TauLacZ . Resulting GSK-3b 2/2 /Brn3a TauLacZ mice were processed for b-Gal histochemistry at E12.5. Trigeminal and DRG axon projections appeared indistinguishable in the two lines. (B) Hippocampal neurons were cultured from GSK-3b null mice for 6 days and stained with antibodies against MAP2 and Tau-1. Note that all neurons have a single axon (red) and multiple dendrites (green). Scale bar = 150 mm. (C) Quantification of the numbers of axons and dendrites in hippocampal cultures from GSK-3b null mice. (D) Parasagittal section of the head from an E14 mouse immunostained with an antibody against GSK-3a. GSK-3a protein is heavily expressed throughout the developing brain. White arrowhead indicates abundant GSK-3a protein in the nerve tract from the trigeminal ganglion (left panel). Br: brain, T: trigeminal ganglion. Parasagittal sections from E14 mice were immunostained with GSK-3a antibody and show strong GSK-a expression in DRGs, spinal axon tracts and spinal nerves (right panel, white arrowheads). Sections were counterstained with DAPI (blue). D: DRG (E) Western blots show GSK-3a is expressed abundantly in various nervous system tissues of GSK-3b null mice.
b activities in in vitro models of axon growth, we turned first to pharmacological inhibitors. We used a recently developed specific GSK-3 inhibitor, 6-bromoindirubin-3 0 -acetoxime, that possesses an IC 50 value in the nanomolar range and shows high selectivity against other proteins that have a similar structure around the ATP binding pocket, including CDK1 (Meijer et al., 2003 (Meijer et al., , 2004 . As an independent pharmacological method to reduce GSK-3, a cell-permeable myristoylated form of GSK-3 peptide inhibitor was also used. The peptide inhibitor is a substrate-specific competitive inhibitor and is selectively recognized by GSK-3 (Plotkin et al., 2003) . We assessed the effects of these inhibitors in neurotrophin-induced axon growth from DRG and sympathetic neurons.
We first cultured an NGF-dependent population of DRG neurons from E14 mice. Treating these cultures with 6-bromoindirubin-3 0 -acetoxime had dose-dependent effects on neurotrophin-induced axon growth. Neurons cultured at a low (10 nM) concentration of 6-bromoindirubin-3 0 -acetoxime exhibited multiple long branches (Figures 2A and S3A ). Although their total axon length was longer than that of controls, there was no difference in the length of the longest axon (Figure 2B) . The branching pattern became more obvious when neurons were treated with 30 nM 6-bromoindirubin-3 0 -acetoxime (Figures 2A and S3A ). Numbers of secondary and tertiary axons were increased, but the length of the longest axon was decreased at this concentration ( Figure 2B ). At 100 and 300 nM concentrations of 6-bromoindirubin-3 0 -acetoxime, concentrations that should produce complete elimination of GSK-3 activity, NGFdependent axon growth of DRG neurons was inhibited in a dose-dependent manner (Figures 2A, 2B , and S3A). Multiple branches were frequently observed, but these were very short. In addition, inhibition of GSK-3 activity caused enlarged and thickened growth cones and axon shafts. These results indicate that GSK-3s are important regulators of axon growth.
In order to confirm that the partial effects at low concentrations of inhibitor are induced by the changes in enzymatic GSK-3 activity, we performed GSK-3 kinase assays. The result showed that GSK-3 activity was partially reduced with the treatments of 6-bromoindirubin-3 0 -acetoxime at low concentrations and greatly suppressed with the inhibitor at high concentrations ( Figure 2B) .
As an independent test of GSK-3 effects on axon growth, we tested the GSK-3 peptide inhibitor on NGFinduced DRG axon growth. Treatment with the peptide Figure 2 . Effects of Pharmacological Inhibition of GSK-3 on NGF-Induced Axon Growth (A) Embryonic DRG neurons were cultured in the presence of NGF and at various concentrations of GSK-3 inhibitors, 6-bromoindirubin-3 0 -acetoxime, and the myristoylated form of GSK-3 peptide inhibitor. Neurons were immunostained with an anti-neurofilament antibody, followed by phalloidin treatment for actin staining. Compared to neurons in the control medium, treatment with GSK-3 inhibitors at 10 nM resulted in multiple axon branches without affecting the length of longest axon. Treatment with GSK-3 inhibitors at 30 nM concentration caused obvious multiple branch formation with shortening of the longest axon. Axon growth was markedly inhibited, and enlarged growth cones were observed at 100 nM and 300 nM concentrations. Scale bar = 50 mm. (B) Quantification of the axon growth defect in neurons treated with GSK-3 inhibitors. Bottom right histogram shows effects of different concentrations of 6-bromoindirubin-3 0 -acetoxime on GSK-3 activity. *p < 0.001, #p < 0.01.
inhibitor also induced multiple branches at low concentrations and blocked axon growth in high concentrations ( Figure 2A ). To determine whether the role of GSK-3 generalizes to other peripheral neuron populations, we cultured dissociated embryonic DRG neurons in the presence of NT-3 and treated them with 6-bromoindirubin-3 0 -acetoxime. In control cultures, neurons had single or two long axons ( Figure S3B ). However, neurons treated with moderate and high dosages of 6-bromoindirubin-3 0 -acetoxime showed short axon growth and branch formation (Figure S3B) . Similar to NGF-induced axons treated with 6-bromoindirubin-3 0 -acetoxime, growth cones and axon shafts of NT-3-induced axons were enlarged and thickened, respectively.
Treatment of GSK-3 inhibitors may affect axonal integrity and neuronal viability. To address these concerns, we first assessed axon growth reversal. DRG neurons were cultured and treated with 6-bromoindirubin-3 0 -acetoxime for a day and then washed out with a fresh medium without inhibitor. We observed that axons started regrowing a few hours after washout, and the growth rates were comparable to controls within 14 hr ( Figure S3C , left panel). We also measured numbers of calcein-positive neurons in each condition. Neuronal viability was not affected by the treatment of 6-bromoindirubin-3 0 -acetoxime ( Figure S3C , right panel). Finally, we cultured NGF-dependent sympathetic neurons from superior cervical ganglia and treated them with 6-bromoindirubin-3 0 -acetoxime. Axon growth was similarly regulated in accordance with degree of reduction of GSK-3 activity (data not shown).
shRNA-Mediated Knockdown of Endogenous GSK-3a and b Inhibits Neurotrophin-Induced Axon Growth of Embryonic DRG Neurons Given that most GSK-3 inhibitors developed thus far have been designed to block the ATP binding pocket of GSK-3 (Meijer et al., 2004) , it is possible that effects on axon growth are not specifically due to GSK-3 inhibition. To address the specificity problem and decisively determine the roles of GSK-3 in axon growth, we generated a plasmid construct (shGSK-3) to knock down endogenous GSK-3s ( Figure S4 ). We selected an oligomer sequence from the early part of the coding region of GSK-3 that is present in both a and b isoforms. A Blast search showed no significant similarity of the oligomer sequence with any other known gene. The plasmid construct coding for GSK-3 shRNA also contains the Venus coding sequence in a separate reading frame with a different promoter. Venus is a variant of YFP and shows brightness about 100-fold more than regular GFP or YFP (Nagai et al., 2002) . Therefore, Venus expression is a good indicator for neurons that overexpress GSK-3 shRNAs.
We first tested whether overexpression of shGSK-3 knocks down endogenous GSK-3s. Western blotting using lysates from shGSK-3-transfected CAD cells showed that GSK-3 levels were strongly suppressed ( Figure 3A ). Then, we examined whether the shRNA had the same effects in DRG neurons. E14 DRG neurons were cultured and transfected with shGSK-3. Three days later, neurons were fixed and immunostained with either GSK-3a or b antibody. Figure 3B shows that there was almost no overlap between neurons (A) Western blot with cellular lysates from neuronal CAD cells that were cultured for 3 days after transfection with shGSK-3 versus control. Both GSK-3a and GSK-3b protein levels were strongly suppressed. (B) DRG neurons were transfected with shGSK-3 and cultured for 3 days. Then the cells were immunostained with anti-GSK-3a (top panels) or b (bottom panels) antibody. The shGSK-3 transfected neurons were Venus positive (white arrowheads) and did not express GSK-3a or b. Nontransfected neurons (star) were positive for both GSK-3a (top panels) and b (bottom panels). Scale bar = 100 mm. (C) Quantification of the percentages of GSK-3 positive staining between shGSK-3-transfected versus nontransfected neurons.
expressing Venus (green) and neurons expressing GSK-3 proteins (red). This result was quantified in Figure 3C . Thus, overexpression of shGSK-3 strongly suppressed synthesis of endogenous GSK-3a and b proteins in cultured DRG neurons. Overexpression of the plasmid vector alone or scrambled shRNA (shScramble) had no effect on endogenous GSK-3 levels ( Figure S5A ).
Next, we sought to determine whether knockdown of GSK-3 inhibits or enhances NGF-dependent axon growth of DRG neurons. DRG neurons were transfected with shRNA, maintained in culture for 3 days to allow for elimination GSK-3 proteins, and then replated in the presence of NGF for 24 hr to assess axon growth. Such replated neurons exhibit more axon branching than neurons cultured at E13 without replating. Nevertheless, there were striking differences in morphology between control versus shGSK-3-transfected neurons. Neurons expressing shGSK-3 showed marked reduction in axon elongation (Figures 4A and 4C) . They also exhibited major alterations in axonal morphology with thickened axons and enlarged and thickened growth cones. NT3-dependent neurons showed a very similar requirement for GSK-3 as shown in Figure 4B . The percentage of neurons with axons was also significantly decreased in association with shGSK-3 overexpression ( Figure 4C ). These findings were further confirmed by transfection with a second shRNA construct with a different sequence (generous gift from Dr. Azad Bonni; Figure S5B ). Overexpression of shScramble in neurons did not cause defects in axon growth (Figures 4A and 4C) , suggesting that the inhibitory effects of shGSK-3 on axon growth are specific.
Recently, it is has been reported that some microRNAs may affect the expression levels of large numbers of genes (Lim et al., 2005) . This raises the issue that shGSK-3 might modulate the expression level of other genes that might induce the observed defects in axon growth. To assess this possibility, we generated the plasmids encoding GSK-3 mutants that have three or six point mutations at wobble positions of the GSK-3b kinase domain. Mutant pGSK-3b-FLAG is hypothesized to have full GSK-3 activity but to be resistant to shRNAinduced degradation due to the mutated nucleotide sequences. In Figure 5A , neurons were transfected with shGSK-3 (Venus) and mutant pGSK-3b-FLAG. Mutant pGSK-3-FLAG rescued the shGSK-3-mediated axon growth inhibition ( Figure 5B ). The longest axon lengths of neurons expressing vector alone and shGSK-3/ mutantGSK-3 were 378.7 6 30 and 362.16 28, respectively ( Figure 5C ). This rescue result directly demonstrated that the axon growth defects we observed with shGSK-3 were indeed caused by the elimination of endogenous GSK-3.
GSK-3 Is Required for Axon Growth of Hippocampal Neurons
We wondered whether GSK-3 also plays important roles for axon growth of CNS neurons. A favored model for CNS axons is specification and subsequent elongation of hippocampal axons. Indeed, recent studies showed that regulation of GSK-3 activity can modulate polarity establishment in hippocampal neurons (Shi et al., 2004; Jiang et al., 2005; Yoshimura et al., 2005) . We therefore cultured hippocampal neurons from E16 mice and treated them with 6-bromoindirubin-3 0 -acetoxime. We examined axon growth at 5-7 days in the absence or presence of 6-bromoindirubin-3 0 -acetoxime. Under our low-density culture conditions as assessed at 5-7 days, one or occasionally two processes were virtually always longer than others even in the presence of GSK-3 inhibitor. Treatment with 6-bromoindirubin-3 0 -acetoxime had major effects on hippocampal axons. Lower concentrations produced striking axonal branching with no reduction in length of the primary axon ( Figures 6A and 6B) . At higher concentrations of 6-bromoindirubin-3 0 -acetoxime, hippocampal neurons had shortened primary axons and elaborated multiple short axonal branches (Figures 6A and 6B) . These effects were generally similar to the effects we observed on neurotrophin-dependent DRG axons although DRG neurons seemed to be somewhat more sensitive to inhibitory effects.
Using transfection of shGSK-3, we achieved knockdown of endogenous GSK-3 in hippocampal neurons ( Figure S6 ). Strong suppression of GSK-3 by the overexpression of shGSK-3 also resulted in axon elongation defects ( Figures 6C and 6D ). shGSK-3-transfected neurons (arrows) exhibited very short axons after 6 days, while nontransfected neurons (stars) extended long axons as expected. Overexpression of shScramble did not affect hippocampal axon growth ( Figures 6C  and 6D ).
GSK-3 and Regenerating Adult Axon Growth
A potentially important issue clinically is whether GSK-3 is required for extension of axons from adult neurons. Adult DRG neurons regenerate their axons robustly after peripheral nerve injury in vivo and in vitro (Smith and Skene, 1997; Neumann and Woolf, 1999) . This axon growth is NGF independent if neurons are cultured on laminin substrate in vitro (Smith and Skene, 1997; Zhou et al., 2006) . To determine whether GSK-3 plays a functional role in this type of axon growth, we first crushed sciatic nerves of 3-month-old mice. After 7 days, L4, 5, and 6 DRGs were isolated and cultured in the presence of 6-bromoindirubin-3 0 -acetoxime. Adult neurons regenerated long axons in the control medium ( Figure S7A ). Regenerating axon growth was inhibited by the treatment of 6-bromoindirubin-3 0 -acetoxime in a dose-dependent manner (Figures S7A and S7B) with prominent axonal branching observed at the lower concentrations.
Ex Vivo Transfection/Slice Analysis of GSK-3 Functions An important caveat of the work described above and all previously reported work on GSK-3 activity and neuronal morphology is that dissociated cultures may not accurately reflect in vivo conditions. To extend our in vitro results and to more accurately model neuronal growth in in vivo conditions, we employed the recently developed technique of ex vivo electroporation and the cortical slice culture. This methodology allows study of individual, genetically altered neurons within an otherwise normal tissue environment. We electroporated either control or shGSK-3 plasmid into the lateral ventricles of E16 embryos and cultured slices of embryonic cortices for 4 days. Slices were then immunostained with neuron specific Tuj1 antibodies and control or shGSK-3 neurons were analyzed by confocal microscopy. Expression of shGSK-3 eliminated endogenous GSK-3 proteins in neurons of cortical slices ( Figure S8 ). Then, we assessed growth of axonal and dendritic processes from developing cortical neurons. Consistent with our results in dissociated cultures, expression of shGSK-3 dramatically reduced the total process lengths and length of the longest process compared to process length of control neurons (Figure 7) . Thus, in a setting where overall structure of the nervous system and neighbor relationships are maintained, GSK-3 activity is required for normal morphological development.
Dephosphorylation of Primed Substrates Induces Axon Branching
Many substrates of GSK-3, including APC and CRMP2, require an additional phosphorylation event (''priming'') by a kinase. Phosphorylation of other substrates by GSK-3b including MAP1B is not known to require actions of a priming kinase. Importantly, APC and CRMP2 have been implicated in the regulation of cell polarity providing a possible link to an axon-branching phenotype if they are dysregulated.
To address this issue, we assessed morphological outcomes associated with two types of dominant-negative GSK-3 constructs. One (GSK-3 R96A) only blocks its activity toward primed substrates Twomey and McCarthy, 2006) while the other (GSK-3 KM) blocks all GSK-3 kinase activity (He et al., 1995; Liu et al., 2002) . We confirmed the properties of these constructs by showing that overexpression of GSK-3 KM suppressed MAP1B phosphorylation, whereas GSK-3 R96A did not affect phospho-MAP1B level in DRG neurons ( Figure 8A ). However, phospho-CRMP2 levels were markedly reduced by either GSK-3 KM or GSK-3 R96A overexpression.
We next examined DRG axon morphogenesis using these mutants. Axon growth was inhibited by GSK-3 KM overexpression to the same extent as strong suppression of GSK-3 activity by high dosages of pharmacological inhibitors or shRNA ( Figures 8B and 8C) . Interestingly, overexpression of GSK-3 R96A induced multiple axon branches without affecting primary axon elongation. Similar changes in axon morphogenesis induced by the two constructs were observed in hippocampal neuron cultures ( Figure 8D ). These results suggest that selective dephosphorylation of primed substrates (CRMP2 and/or APC) induces axon branching, whereas dephosphorylation of all substrates prevents axon growth.
Differential Sensitivities of APC/CRMP2 versus MAP1B to GSK-3 Inhibition
We next asked whether different levels of GSK-3 inhibition with pharmacological inhibitors were associated with differential effects on these two classes of substrates. We first examined whether changes in the distribution of APC along the axon could be changed at low levels of GSK-3 inhibition. We cultured DRG neurons and treated them with 6-bromoindirubin-3 0 -acetoxime at various concentrations. Western blots revealed no change in total amount of APC protein, even at the highest concentration of GSK-3 inhibitor (data not shown). Neurons were then immunostained with an anti-APC antibody. Neurons treated with low concentrations (30 nM) of inhibitor showed multiple APC accumulation spots along the axon shaft, including at branching points (Figure 9A , arrows), while control neurons had distinct APC accumulation at the tip of the growth cone ( Figure 9A ). The numbers of these multiple APC accumulation spots increased in accordance with increasing concentration until virtual confluence was achieved at the highest concentration (300 nM) of 6-bromoindirubin-3 0 -acetoxime. Quantification of fluorescence intensity confirmed the morphological appearance demonstrating multiple peaks ( Figure 9B , pink) along the axon shaft with the treatment of 30 nM 6-bromoindirubin-3 0 -acetoxime while a single dominant peak ( Figure 9B , blue) was seen at the axon tip with control medium treatment ( Figure 9B ). There was no dominant peak ( Figure 9B , sky blue) of APC immunofluorescence intensity along the axon with higher concentrations of 6-bromoindirubin-3 0 -acetoxime. Suppression of GSK-3 activity by shGSK-3 overexpression resulted in a similar APC distribution pattern to that observed with higher levels of pharmacological inhibition ( Figure S9A ).
Like APC, the interaction of CRMP2 with tubulin is suppressed when it is phosphorylated by GSK-3 (Yoshimura et al., 2005) . Treatment with GSK-3 inhibitor at 10 nM markedly diminished CRMP2 phosphorylation ( Figure 9C ). The phosphorylation level was further reduced at 30 nM concentration and almost completely eliminated at 100 nM concentration of 6-bromoindirubin-3 0 -acetoxime. Pharmacological inhibitors of GSK-3 activity are known to decrease the level of phosphorylated MAP1B (Goold et al., 1999; Dent and Gertler, 2003; Owen and Gordon-Weeks, 2003). We confirmed that this effect is due to GSK-3 inhibition by overexpressing shGSK-3 in the DRG culture and measuring the phophorylated-MAP1B level. Lysates of cells with GSK-3 knockdown had reduced levels of phosphorylated-MAP1B (Figure S9B) . We next assessed MAP1B phosphorylation in the presence of different concentrations of 6-bromoindirubin-3 0 -acetoxime. The level of phosphorylated MAP1B was essentially not changed at 10 and substantially maintained at 30 nM of inhibitor treatment (Figure 9C) . The phosphorylation level was markedly decreased at 100 nM and almost eliminated at 300 nM concentration. Thus, MAP1B is still phosphorylated at lower levels of GSK-3 inhibition (10 or 30 nM) where there is almost no CRMP2 phosphorylation ( Figure 9C ). 
Discussion
In this study, we have found that neurotrophin-induced axon growth, development of hippocampal neuronal polarity, and gross nervous system development all occur surprising normally in GSK-3b null mice. A potential explanation for this relatively normal nervous system development in the absence of GSK-3b is the high levels of expression of the closely related family member GSK-3a in many populations of neurons. Indeed, strong inhibition of GSK-3 activity via highly specific pharmacological inhibitors, peptide inhibitors, a kinase-dead construct, and specific elimination of both GSK-3a and GSK-3b isoforms with shRNA all markedly reduced axon growth in widely employed experimental paradigms. In contrast, mild to moderate inhibition of GSK-3 activity using pharmacological or peptide inhibitors did not reduce overall axon growth, but rather induced axon branching. Finally, elimination of activity toward primed substrates only was also associated with axon branching rather than an overall reduction in axon growth.
Compensation of GSK-3b Function by the a Isoform GSK-3b null mice die within a few hours after birth. Interestingly, however, their nervous systems, including brain, spinal cord, and DRG show no gross morphological abnormalities ( Figures 1A, S1A , and S1B). Moreover, neurons in primary DRG (data not shown) and hippocampal cultures ( Figures 1B and S1C ) from the null and control mice did not exhibit any difference in axon growth. These findings raise the possibility of compensation by the a form of GSK-3 when GSK-3b is missing. GSK-3a and b show high sequence homology and display more than 98% sequence identity within the kinase domain (Woodgett, 1990) . Our results regarding their expression patterns revealed that they are abundantly coexpressed in the same places throughout the nervous system ( Figure S2 ). Indeed, GSK-3a appears to be particularly abundant in axons ( Figures 1D and S2C ). Functional compensation is strongly suggested by our results. Either pharmacological inhibition or genetic ablation of both GSK-3a and b strongly inhibited axon growth. Rescuing axon growth by mutant GSK-3b alone also supported the idea of functional redundancy between the isoforms. Although GSK-3 isoforms may well have unique functions in certain circumstances, based on our observations, roles of the two forms appear to overlap in the regulation of axon morphology.
GSK-3 Activity Is Required for Efficient Axon Growth
Although the elimination of GSK-3b activity alone in knockout mice has little noticeable effect on axon growth in standard experimental paradigms, the results of our study are unequivocal in demonstrating that GSK-3 activity is required for efficient elongation of axons in vitro. Thus, when activities of both GSK-3a and GSK3b are eliminated by either specific pharmacological inhibitors or shRNAs, axon growth is markedly impaired. Axons are short, thickened, and studded with multiple actin-rich protrusions along their shafts. Interestingly, growth cones are not collapsed; in fact, growth cone lamellopodia are enlarged compared to controls: this is consistent with previous studies (Lucas et al., 1998; Goold et al., 1999; Krylova et al., 2002; Owen and Gordon-Weeks, 2003) . Valerio et al. (2006) also recently showed that inhibition of GSK-3 by leptin increases axonal growth cone size in developing cortical neurons. Thus, elimination of GSK-3 activity strongly interferes with appropriate regulation of microtubules but either directly or indirectly enhances actin polymerization in lamellopodia. This latter result is consistent with observations that semaphorin-induced growth cone collapse is associated with increased GSK-3 activity (Eickholt et al., 2002; Chadborn et al., 2006) .
Our results suggest a very general requirement for appropriate regulation of GSK-3 in mediating axon growth. Thus, we found essentially similar results in three types of peripheral neurons responsive to different members of the neurotrophin family, late embryonic hippocampal neurons presumably representative of many CNS populations, and adult ''regenerating'' DRG neurons. In each of these settings, reducing GSK-3 activity leads to axon branching, and elimination of GSK-3 activity markedly impaired axon growth. Further, we demonstrate a requirement for GSK-3 activity in axon growth of cortical neurons after ex vivo electroporation in a cortical slice preparation where normal neuronal architecture and cellular context are largely preserved.
The potential importance of our findings is demonstrated by the large number of reports that GSK-3 is an essential component of signaling pathways associated with morphological changes. Thus, canonical signaling via all Wnt family members is thought to require appropriate regulation of GSK-3s as are signaling via many receptor tyrosine kinases, the hedgehog pathway, leptins, and presumably other pathways. Importantly GSK-3 is positively regulated via semaphorins and other mediators that induce growth cone collapse (Eickholt et al., 2002; Chadborn et al., 2006) . Our findings suggest that GSK-3s are key regulators of axon morphology downstream of multiple extracellular signals and signaling pathways.
Controversy about GSK-3 Activity and Regulation of Neuronal Morphology
Several reports have shown that inhibition of GSK-3b activity by Wnts or lithium decreased axon elongation and induced axon branching in DRG and cerebellar neurons (Lucas et al., 1998; Krylova et al., 2002; Owen and Gordon-Weeks, 2003; Goold and Gordon-Weeks, 2005) . Shi et al. (2004) also observed that inhibition of GSK-3b activity led to a defect in axon development in hippocampal neurons. Our group recently demonstrated that inactivation of GSK-3 is required for efficient NGF-induced axon elongation of DRG neurons but that such inactivation must be spatially localized at the distal axon (Zhou et al., 2004 (Zhou et al., , 2006 . However, two recent studies showed that multiple long axons were induced in the hippocampal culture setting of GSK-3b inhibition, suggesting that global inhibition of GSK-3b may enhance axon growth (Jiang et al., 2005; Yoshimura et al., 2005) . These latter results have important clinical Figure 8 . Effects of GSK-3 KM and GSK-3 R96A on Axon Morphogenesis (A) Phospho-MAP1B and phospho-CRMP2 levels were measured using western blotting with lysates from DRG neurons transfected with GSK-3 KM or GSK-3 R96A mutant. Overexpression of GSK-3 KM mutant suppressed phosphorylation of both MAP1B and CRMP2, whereas GSK-3 R96A only inhibited CRMP2 phosphorylation. (B) Embryonic DRG neurons were transfected with either GSK-3 KM or GSK-3 R96A mutant and cultured. To assess the axon morphogenesis, neurons were then immunostained with anti-neurofilament antibody and phalloidin. Because the GSK-3 mutants have an HA tag, neurons that express GSK-3 mutant were identified by immunostaining with HA antibody. Neurons expressing GSK-3 KM mutant had very short axons relative to control. However, GSK-3 R96A expression induced multiple axons without affecting length growth of each axon. Scale bar = 30 mm. implications in suggesting that GSK-3 inhibitors could be important in promoting axon growth after neuronal injuries.
One potential source of confusion is the difference in pharmacological reagents used to inhibit GSK-3 activity. Lithium, SB216763, SB415286, and ARA014418 are the most often used drugs in the studies. A potential problem is that some of these drugs show low selectivity and high IC 50 values (Knockaert et al., 2002; Fischer, 2003; Meijer et al., 2004 ). Thus, it is possible that growth inhibitory effects observed in some prior studies were due to effects of the inhibitors on other structurally similar kinases such as cyclin-dependent kinases that may influence morphology. In contrast, 6-bromoindirubin-3 0 -acetoxime used in our study possesses lower IC 50 value and shows higher selectivity than those of other inhibitors (Meijer et al., 2003 (Meijer et al., , 2004 . As an additional independent method to check our conclusion, we used a membrane-permeable peptide inhibitor that was previously shown to be a selective, substrate-specific, and competitive inhibitor (Plotkin et al., 2003) . We observed the same defects in axon growth with both 6-bromoindirubin-3 0 -acetoxime and the GSK-3 peptide inhibitor. We confirmed the axon growth-inhibiting effect of strong GSK-3 inhibition with an shRNA approach. In our hands, a previously published shRNA associated with elaboration of multiple axons by hippocampal neurons (Yu et al., 2003) did not lead to strong knockdown of GSK-3b protein. Therefore, we selected alternative sequences and demonstrate here that the sequences we selected strongly suppress the synthesis of both endogenous GSK-3b and a proteins. We confirmed the specificity of our shRNA by showing that scrambled sequences had no effect and that co-overexpression of a mutant GSK-3b plasmid which encodes wild-type GSK-3b but contains several mismatches at wobble positions ''rescued'' biological function. Our results with GSK-3 shRNA demonstrate that strong suppression of endogenous GSK-3s inhibited axon growth in multiple paradigms including in adult DRG ''regenerative'' axon growth. Finally, we demonstrated in an ex vivo electroporation/cortical slice protocol that this shRNA strongly reduced GSK-3s in cortical neurons and led to dramatic shortening of cortical neuronal axons in a setting where normal architecture and cellular interactions are preserved.
In our view, the explanation for prior differences in experimental results is that different degrees of GSK-3 inhibition are associated with different morphological outcomes, as we have demonstrated. Our results showed that axon growth was inhibited by the treatment with 6-bromoindirubin-3 0 -acetoxime at high concentrations (Figure 2 ). Neurons treated with lower concentrations of 6-bromoindirubin-3 0 -acetoxime, however, Figure 9 . Differential Sensitivities of Negatively versus Positively Regulated GSK-3 Substrates (A) Embryonic DRG neurons were cultured and treated with 6-bromoindirubin-3 0 -acetoxime at 0 nM, 30 nM, and 300 nM concentrations. Neurons were immunostained with anti-tubulin antibody (white) and an anti-APC antibody (red). Boxed areas in left panels were magnified in right panels. APC accumulated at the tip of axon in control medium, and multiple APC accumulation spots were seen in 30 nM inhibitor-treated cultures. APC accumulation was diffuse along axons with 300 nM inhibitor treatment. (B) Intensity of APC staining in (A) was measured along axons and recalculated to relative intensity. Left panel shows APC intensity scan of each condition. APC staining in control culture (blue) revealed a dominant peak in the vicinity of the axon tip, while APC staining at a concentration of 30 nM inhibitor (pink) showed multiple peaks along the axon. In contrast, 300 nM inhibitor treatment (sky blue) induced a highly sustained pattern of APC staining throughout the axon shaft. (C) DRG cultures were treated with various concentrations of 6-bromoindirubin-3 0 -acetoxime, and phospho-CRMP2 and phospho-MAP1B levels were measured using Western blotting (left panels). Band intensity of phospho-CRMP2 and phospho-MAP1B blots was measured and recalculated to relative intensity (right panel). Unphosphorylated forms of CRMP2 and MAP1B were used to normalize the band intensity of phospho forms. Signals were quantified using NIH Image software and represented by relative intensity versus control. The phospho-CRMP2 level was markedly diminished at 10 nM and 30 nM 6-bromoindirubin-3 0 -acetoxime concentration. In contrast, the MAP1B phosphorylation level was relatively maintained at 10 and 30 nM 6-bromoindirubin-3 0 -acetoxime treatments and was markedly reduced at 100 and 300 nM.
developed multiple long branches that increased total axon length (Figure 2 ), which is consistent with previous reports (Jiang et al., 2005; Yoshimura et al., 2005) . Munoz-Montano et al. (1999) also observed a similar neurite growth pattern in that the percentage of cerebellar neurons with countable neurites was increased with lithium treatment at low concentration while it was decreased with high concentration of lithium. Indeed, this interesting effect observed with partial GSK-3 inhibition is consistent with the therapeutic roles for GSK-3 inhibitors over a certain concentration range. However, our results are unequivocal in showing that strong suppression of GSK-3 activity profoundly disrupts axon growth.
GSK-3 Coordinates Activities of Downstream Microtubule-Associated Proteins to Produce Axon Branch Formation or Elongation
In exploring mechanisms for our results, it is important to keep in mind that there are multiple microtubuleassociated GSK-3 substrates. Some substrates like APC and CRMP2 require the action of a priming kinase and are inactivated by GSK-3-induced phosphorylation. APC binds to microtubule (+) ends when it is dephosphorylated (Zumbrunn et al., 2001) and is thought to stabilize plus ends (Shi et al., 2004; Zhou et al., 2004) . Dephosphorylated CRMP2 participates in the assembly of tubulin heterodimers during microtubule polymerization (Fukata et al., 2002) . MAP1B is representative of another class of substrates that do not require actions of a priming kinase and that are thought to be activated by GSK-3 phosphorylation. MAP1B is known to regulate microtubule dynamics in the axon shaft (Goold and Gordon-Weeks, 2005) . Inhibition of GSK-3 activity decreases the level of phosphorylated-MAP1B and dampens microtubule dynamics (Goold et al., 1999; Owen and Gordon-Weeks, 2003; Dent and Gertler, 2003) . In order to explore the effects of activating primed substrates specifically, we used two types of dominant-negative GSK-3 constructs, GSK-3 KM and GSK-3 R96A, with actions toward all GSK-3 substrates or only primed substrates, respectively. Overexpression of GSK-3 KM that markedly reduces both MAP1B and CRMP2 phosphorylation and strongly inhibited axon growth and produced thickened axons and enlarged growth cones in all respects similar to strong GSK-3 inhibition with high-dose pharmacological inhibitors or shRNAs (Figure 8) . Interestingly, however, overexpression of GSK-3 R96A that only suppresses phosphorylation of primed substrates such as CRMP2 induced multiple axon branches without affecting primary axon elongation. These results show that preferential suppression of GSK-3 activity toward substrates requiring actions of a priming kinase is associated with a disorder of axon polarity (branching) rather than complete inhibition of axon growth. Consistent with the above results, moderate levels of GSK-3 inhibition with pharmacological inhibitors resulted in different effects on primed versus unprimed substrates (Figure 9 ). Thus, phosphorylation of CRMP2 is markedly diminished at 10 nM and 30 nM and almost completely eliminated at 100 nM concentrations of 6-bromoindirubin-3 0 -acetoxime. Although we do not have access to an antibody specific for phospho-APC, we observed changes in APC distribution along the axon with as little as 10 nM 6-bromoindirubin-3 0 -acetoxime. In contrast, there was little change in the phosphorylation of MAP1B at 10 and 30 nM 6-bromoindirubin-3 0 -acetoxime. Further, some phosphorylation of MAP1B persisted at 100 nM. We propose that these striking differences in sensitivities of GSK-3 substrates toward the different degrees of GSK-3 inhibition may be associated with different effects on axon morphogenesis.
A Proposed Model for GSK-3 Regulation of Axon Morphogenesis
Based on our results and previous studies, we propose a model for axon growth regulated by GSK-3 (Figure 10 ). When axons are rapidly elongating as is observed in the setting of neurotrophin stimulation, elongation of a single hippocampal axon or regeneration of DRG axons after peripheral nerve injury, GSK-3 is locally inactivated near the growth cone ( Figure 10A ). Such localized (polarized) inactivation promotes binding of primed GSK-3 substrates such as APC and CRMP2 to microtubules. At the same time, activity toward other GSK-3 substrates that are positively regulated by GSK-3 such as MAP1B is preserved, leading to optimal conditions for a pool of dynamic microtubules, stabilization at the microtubule plus end, efficient addition of tubulin dimers, and microtubule polymerization. It is surprising and elegant that regulation of GSK-3 appears to activate and inactivate different substrates at the same time in the course of regulating microtubule assembly.
When GSK-3 activity is strongly suppressed by high dosages of pharmacological or peptide inhibitors, expression of a kinase-dead GSK-3 construct or expression of an shRNA that strongly reduces expression of both GSK-3a and b, axon growth is strongly disrupted ( Figure 10B ). We hypothesize that strong, global GSK-3 inhibition results in excessive microtubule stability all along the axon shaft due to the inhibition of MAP1B that eliminates dynamic microtubules and the abnormal distribution of APC that stabilizes microtubules all along the axon shaft. In this case, there is no pool of dynamic microtubules at the growth cone, known to be necessary for growth cone advance, and no localization of APC to microtubule plus ends.
Finally, we propose that partial inhibition due to low concentrations of inhibitors or inhibition of primed substrates only produces an intermediate condition (Figure 10C ). In this case, MAP1B activity and a pool of dynamic microtubules are preserved leaving the capacity for primary axon or branch elongation. Presumably, both the low concentrations of inhibitors and the R96A construct produce a nonpolarized dephosphorylation of primed substrates and multiple spots of APC accumulation providing nodes for axon branches. In this situation, active GSK-3 substrates that are present at the branch points and branch tips provide the pool of dynamic microtubules for pronounced axon growth.
Of course, additional complexity would be observed in vivo. One can imagine that the combination of several extracellular cues may induce different spatial and temporal distributions of GSK-3 activities in vivo. Indeed, activity of GSK-3 is influenced by multiple extracellular molecules including Wnts, NGF, EGF, IGFs, hedgehog, semaphorin, insulin, and amino acids that may be encountered by growing or regenerating axons. As a result, many different morphological outcomes could result from GSK-3 regulation.
Clinical Implications
The regulation of GSK-3 activity has been a major pharmacological intervention point due to the clinical implications for the treatment of diseases such as bipolar disorders, Alzheimer's disease, Parkinson's disease, and diabetes (Meijer et al., 2004) . The strong regulatory effects of GSK-3 on axon growth have raised the possibility of modulating its activity to promote regeneration after spinal cord injury. Our results emphasize the importance of dosage effects and the appropriate spatial regulation of GSK-3 substrates. These issues need to be considered in any clinical trial of GSK-3 inhibitors in spinal cord injury to ensure that GSK-3 inhibitors are administered in a way that would help rather than hinder regeneration and recovery.
Experimental Procedures
Materials 6-bromoindirubin-3 0 -acetoxime (Calbiochem), membrane-permeable GSK-3 peptide inhibitor (Calbiochem), laminin (BD Science), poly-D-lysine (Sigma), mouse NGF (Harlan Bioproducts), human NT-3 (Promega), B27 supplements (Invitrogen), N2 supplement (Invitrogen), and alexa-phalloidin (Molecular Probe) were purchased.
Plasmids
To generate shGSK-3, we synthesized an oligomer (5 0 -GAACCGA GAGCTCCAGATC-3 0 ) and its complement using an shRNA selection program maintained by the Bioinformatics and Research computing at MIT (http://jura.wi.mit.edu/bioc/siRNAext). A Blast search demonstrated that the oligomer sequence did not show significant similarity with any known gene. The oligomers were annealed and inserted into BglII/HindIII sites of pSuper-Basic vector (OligoEngine, Inc.), which was modified with the insertion of the Venus (Nagai et al., 2002) coding sequence together with the CMV promoter into the XhoI restriction site 3 0 to the oligomer. The scrambled sequence of shGSK-3 was used for shScramble, which was generated by the same strategy as the one used for shGSK-3.
pGSK-3-FLAG was generously provided by Dr. Xiao-Fan Wang (Duke University). Mutant GSK-3 was made using WT pGSK-3-FLAG. Three or six nucleotides were mutated at wobble positions in the GSK-3 kinase domain using Quik Change Multi Site-Directed Mutagenesis kit (Stratagene).
Primary Neuronal Cultures
Mouse embryonic dorsal root ganglia (DRG) culture was performed as described in a previous published paper (Markus et al., 2002; see Supplemental Experimental Procedures) .
Embryonic hippocampal neurons were cultured by the method of Goslin et al. (1998) (see Supplemental Experimental Procedures) .
Adult DRG neuron cultures from control mice and mice in which the sciatic nerve had been crushed 1 week previously were prepared as described in Zhou et al. (2006) (see Supplemental Experimental Procedures).
Neuronal Transfection
Mouse DRG or hippocampal neurons were transfected with various plasmids as described in a previous paper (Zhou et al., 2004) . Briefly, dissociated neurons suspended in 100 ml of Amaxa electroporation buffer with 2-10 mg plasmid DNA. Suspended cells were then transferred to Amaxa electroporation cuvette and electroporated with an Amaxa Nucleofector apparatus set on G-13 program. After electroporation, cells were immediately plated onto coated coverslips. After neurons fully attached to the substrates (2-4 hr), the medium was changed to remove the remnant transfection buffer.
Immunocytochemistry and Morphometry
Neurons were immunostained according to protocols described in Zhou et al. (2004) (see Supplemental Experimental Procedures) . Primary antibodies were used at the following dilutions: 1:1000 for mouse-anti-tubulin (Sigma), 1:500 for mouse-anti-GSK-3b (BD Transduction Laboratory), 1:500 for rabbit anti-GSK-3a (Upstate), 1:500 for rabbit anti-neurofilament (Sigma), 1:1000 rabbit anti-APC (Santa Cruz), and 1:500 for rabbit anti-FLAG (Sigma). Secondary antibodies were used at the following dilutions: 1:1000 for goat antimouse Alexa 647, 1:1000 for goat anti-mouse Alexa 594, 1:1000 for goat anti-mouse Alexa 488, 1:1000 for goat anti-rabbit Alexa 488, 1:1000 for goat anti-rabbit Alexa 594 from Molecular probe.
Images were taken with Metamorph software (Molecular Devices) and Hamamatsu Orca ER CCD camera attached to a Nikon Eclipse microscope. All image analysis for measuring axon length, percent of neurons with axons, and intensity of immunostained samples were done with IPLab software (Scanalytics) or Metamorph software. Only neurons with axons longer than two cell bodies were counted. More than 100 neurons were analyzed in each condition. Statistical significance was determined with independent t test and one way ANOVA followed by Tukey's post hoc test. Data were presented as mean 6 SEM.
Western Blotting
Cellular lysate was prepared using RIPA buffer and the protein content was determined by a Bio-Rad Protein Assay system. Proteins were separated on 3%-8% or 4%-12% SDS-PAGE gradient gel and transferred onto nitrocellulose membrane. Then the membrane was incubated with SMI31 (Sternberger Immunocytochemicals), rabbit anti-MAP1B (Chemicon), rabbit anti-GSK-3a, mouse anti-GSK-3b, rabbit anti-phospho-GSK-3b antibody (Cell Signaling), or rabbit anti-phospho-CRMP2 (Yoshimura et al., 2005) at 4 C overnight. The secondary antibody used was donkey anti-mouse or anti-rabbit IgG conjugated to HRP (Amersham) and the ECL reagents (Amersham) were used for immunodetection.
GSK-3 Activity Assay DRG neurons were cultured and lysed with RIPA buffer. The lysate was centrifugated at 10,000 3 g for 10 min, and the supernatant was removed. Then cellular GSK-3b was immunoprecipitated with anti-GSK-3b antibody. Kinase activity was assayed in a total volume of 15 ml of kinase buffer containing 20 mM Tris (pH 7.5), 5 mM MgCl 2 , 1 mM dithiothreitol, 250 mM ATP, 1.4 mCi of [g-32 P]ATP, and 100 mM phosphoglycogen synthase peptide-2 (YRRAAVPPSPSLSRHSSPH QSEDEEE; Upstate Biotechnology). The samples were incubated for 30 min at 30 C and placed on ice for 2 min before centrifugating for 3 min at 1800 3 g. The reaction supernatants were spotted onto P81 filter paper, and the filters were washed four times in 0.5% phosphoric acid for 1 hr. The filters were further washed for 2 min in 95% ethanol, air-dried, and counted in a liquid scintillation counter.
Ex Vivo Electroporation and Cortical Slice Culture
Lateral ventricle of E16 embryos were injected with 2.5 mg/ml of either shScramble or shGSK-3 using a Picospritzer (Parker Instrument). Brains were then subjected to electroporation under the following electroporation parameters: 70 V, pulse duration 100 ms, pulse interval 100 ms, and 8 pulses. Electroporated cerebral hemispheres were dissected and sectioned coronally into 200 mm thick slices by using a vibratome (VT1000S, Leica, or NVSLM1 motorized vibratome from Precision Instrument). Cortical slices were transferred onto nucleopore membrane filters (Whatman) and maintained in vitro for 4 days in MEM (Invitrogen) supplemented with 10% FBS, 100 mg/ml penicillin/streptomycin. Slices were then fixed and immunostained as described earlier and imaged by using a confocal microscope (Zeiss).
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